In the European Union, regulators are agonizing over more than just clinical trials.

With backing from pharma and high hopes, Eu takes steps to improve front-end approaches to R&D.

New regulations prompt the EU to request more info from sponsors on clinical trial applications.

Some of the tangible outcomes expected to emerge from a pediatric network include scientific and operational quality standards.

Historic public–private initiative to boost biomedical research adopted by EU and applauded by industry.

EMEA and EC admit to legislation difficulties, and many voice their ideas in an effort to make improvements.

Expect a raft of new or revised EU guidelines for efficacy testing of pharmaceuticals in '08.

Europe took a step toward improving the operation of its much-criticised clinical trials directive on October 3—but only a step.

Europe's clinical trial community has a lot to say about the EMEA's draft guidance on first studies in man.